Really? Any time you have a look at interim results the blind is compromised. That is one of the primary tradeoffs of an adaptive trials. Interim results are part of the trial design and are used to determine the number if addtiional patients that will be needed to properly power the trial (oh andBTW whether the trial should be stopped for futility) but the blind is compromised. You don't neeed to worry that the FDA will spit on ONCT's face with the current data because it won't ever get to the FDA. Not that it matters but ONCY's trial is now a complete mess. In fact it is now 2 trials both with compromised blinds, PFS's that can't be explained and which are beyond the wildest assumptions used in the trial design. And no scientific explanation why REO should work differently in mets. Oh wait Coffey said his "working hypothesis is that primary's are "fibrous" and somehow block the large reo molecule but lets small molecules through (which is why reo has NO effect on locoregional tumors.)" Really? Really?